| Schedule of segment reporting information, by segment |
| | | | | | | | | | | | | Three Months Ended June 30, | | Six Months Ended June 30, | | 2025 | | 2024 | | 2025 | | 2024 | Revenue | $ | 2,733,000 | | $ | 57,000 | | $ | 2,790,000 | | $ | 113,000 | Less: | | | | | | | | | | | | Acquired in-process research and development | | — | | | 117,464,000 | | | — | | | 117,464,000 | Research and development expenses: | | | | | | | | | | | | Preclinical and clinical development | | 1,897,475 | | | 624,000 | | | 2,524,475 | | | 1,333,000 | Personnel related | | 425,000 | | | 1,306,000 | | | 890,000 | | | 1,979,000 | Other research and development (a) | | (31,475) | | | 2,034,000 | | | 1,382,525 | | | 2,564,000 | Total research and development expenses | | 2,291,000 | | | 3,964,000 | | | 4,797,000 | | | 5,876,000 | General and administrative expenses: | | | | | | | | | | | | Professional and consulting fees | | 634,000 | | | 5,000 | | | 1,826,000 | | | 2,083,000 | Personnel related | | 512,000 | | | 1,120,000 | | | 1,416,000 | | | 1,892,000 | Other general and administrative (b) | | 545,000 | | | 852,000 | | | 1,203,000 | | | 1,358,000 | Total general and administrative | | 1,691,000 | | | 1,977,000 | | | 4,445,000 | | | 5,333,000 | Change in fair value of warrant liability | | (146,000) | | | — | | | (26,659,000) | | | — | Other income, net | | (188,000) | | | (205,000) | | | (368,000) | | | (434,000) | Net income (loss) | $ | (915,000) | | $ | (123,143,000) | | $ | 20,575,000 | | $ | (128,126,000) | | | | | | | | | | | | |
| (a) | Other research and development expenses include stock based compensation, manufacturing, formulation, development, and consulting fees. |
| (b) | Other general and administrative expenses include stock based compensation, public company costs, and insurance. |
|